Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H42N2O8 |
Molecular Weight | 498.6096 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]([C@H](O)[C@@H](O)[C@H](O)\C=C\C(C)(C)C)C(=O)N[C@H]1CC[C@H](CNC1=O)OC(=O)C2CCCCC2
InChI
InChIKey=XSYJUVKQRPLTAU-BKMGADMVSA-N
InChI=1S/C25H42N2O8/c1-25(2,3)13-12-18(28)19(29)20(30)21(34-4)23(32)27-17-11-10-16(14-26-22(17)31)35-24(33)15-8-6-5-7-9-15/h12-13,15-21,28-30H,5-11,14H2,1-4H3,(H,26,31)(H,27,32)/b13-12+/t16-,17+,18-,19+,20-,21-/m1/s1
Molecular Formula | C25H42N2O8 |
Molecular Weight | 498.6096 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:04:57 GMT 2023
by
admin
on
Sat Dec 16 11:04:57 GMT 2023
|
Record UNII |
XAE4WV436T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
XAE4WV436T
Created by
admin on Sat Dec 16 11:04:57 GMT 2023 , Edited by admin on Sat Dec 16 11:04:57 GMT 2023
|
PRIMARY | |||
|
270902-51-7
Created by
admin on Sat Dec 16 11:04:57 GMT 2023 , Edited by admin on Sat Dec 16 11:04:57 GMT 2023
|
PRIMARY | |||
|
9892113
Created by
admin on Sat Dec 16 11:04:57 GMT 2023 , Edited by admin on Sat Dec 16 11:04:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antineoplastic, Azepine; Mechanism of Action: Aminopeptidase inhibitor; Highest Development Phase: Discontinued for Chronic lymphocytic leukaemia, Multiple myeloma and Non-Hodgkin's lymphoma
|
||
|
ACTIVE MOIETY |
Seventy-eight cycles of treatment have been administered (mean 2.5, range 1-10 mg/day). Four cardiovascular dose-limiting toxicities were reported at 30 mg (2/2 patients) and 25 mg (2/9 patients), eight additional patients at various dose levels had (cardio)vascular toxicity, probably drug related, and one patient died owing to pulmonary embolism at the 5 mg dose. No objective responses were recorded. Pharmacokinetic parameters were variable, although linear and without obvious accumulation from cycle I to cycle II. LAF389 dose escalation was terminated owing to occurrence of unpredictable cardiovascular events. This, associated with the lack of clinical activity, did not warrant further investigation of this agent.
|
||
|
ACTIVE MOIETY |
An optimized, convergent, safe synthesis of LAF389 (9), an anti-cancer agent analogous to bengamide B, is described.
|